SST and cancer: Two new 99mTc-labelled SST analogs were introduced in the 1990s: [99mTc]Tc-N4-[Tyr3] Octreotate (Demotate®, POLATOM, Otwock, Poland) and [99mTc]Tc-EDDA/HYNIC-[Tyr3] Octreotide (Tektrotyd®, POLATOM, Otwock, Poland), which have been broadly used in medical practice in patients with several SSTR+ cancers [22,23,24].